4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Mama>98.5% (HPLC) Lenvatinib Mesylate Intermediate Factory
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates ma maualuga mama
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igoa Vailaau | 4-Chloro-7-Methoxyquinoline-6-Carboxamide |
Synonyms | 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib Le mama 12;Lenvatinib Le mama B;Lenvatinib Le mama LFS-B |
Numera CAS | 417721-36-9 |
CAT Numera | RF-PI1971 |
Tulaga Fa'asoa | I Fa'atauga, Gaosi Gaosi 50MT/Tausaga |
Fuafua mole | C11H9ClN2O2 |
Molecular Weight | 236.65 |
Lisi Lisi | >205℃ (tes.) |
Malosi | 1.380±0.060g/cm3 |
Fa'ailoga | Ruifu Chemical |
Aitema | Fa'amatalaga |
Fa'aaliga | Pa'epa'e-Pa'epa'e i le Pa'u Samasama Malamalama |
Mama / Suʻesuʻega Metotia | >98.5% (HPLC) |
Ma'imau ile Fa'amago | <0.50% |
Toega i luga o le mumu | <0.50% |
Aofa'i Fa'aleaga | <1.50% |
Proton NMR Alaleo | E tusa ai ma le Fauga |
Tulaga Su'ega | Pisinisi Tulaga |
Fa'aoga | Intermediate o Lenvatinib Mesylate (CAS: 857890-39-2) |
afifi: Fagu, ato pepa alumini, 25kg/Kati Pusa, pe tusa ai ma manaoga o tagata faatau
Tulaga teuina:Teu i totonu o pusa faʻamaufaʻailoga i se nofoaga malulu ma mago;Puipui mai le malamalama ma le susu
4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) e masani ona faʻaaogaina e avea o se vaeluaga ole Lenvatinib Mesylate (CAS: 857890-39-2).Na atiaʻe e Eisai Inc., lenvatinib mesylate o se vascular endothelial growth factor receptor (VEGF) inhibitor o loʻo i ai le gaioiga e faasaga i le VEGF subtypes 1, 2, ma le 3 ma na faʻatagaina e le FDA i le 2015 mo le togafitiga o le kanesa thyroid eseese lea e faʻapitonuʻu. faifai pea, metastatic, poʻo le alualu i luma ma e leʻi tali atu i togafitiga iodine radioactive.I le masina o Me 2016, na faʻamaonia ai e le FDA le vailaʻau e avea o se togafitiga faʻatasi ma everolimus mo le togafitiga o le gasegase o le tino.Talu ai ona o le VEGF (ma le fibroblast growth factor receptors, ua taʻua o FGFRs) e manatu e faia se sao i ala cardiovascular signaling, o le VEGF2R ma le FGFR inhibition o loʻo manatu o auala ia i tua atu o aʻafiaga muamua o le lenvatinib mesylate, o le toto maualuga.